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Abstract
Objectives
To update the epidemiology of S. aureusbloodstream infection (SAB) in a high-income
country and its link with infective endocarditis (IE).
Methods
All consecutive adult patients with incident SAB (n = 2008) were prospectively enrolled be-
tween 2009 and 2011 in 8 university hospitals in France.
Results
SAB was nosocomial in 54%, non-nosocomial healthcare related in 18% and community-
acquired in 26%. Methicillin resistance was present in 19% of isolates. SAB Incidence of
nosocomial SAB was 0.159/1000 patients-days of hospitalization (95% confidence interval
[CI] 0.111-0.219). A deep focus of infection was detected in 37%, the two most frequent
were IE (11%) and pneumonia (8%). The higher rates of IE were observed in injecting drug
users (IE: 38%) and patients with prosthetic (IE: 33%) or native valve disease (IE: 20%) but
40% of IE occurred in patients without heart disease nor injecting drug use. IE was more fre-
quent in case of community-acquired (IE: 21%, adjusted odds-ratio (aOR) = 2.9, CI = 2.0-
4.3) or non-nosocomial healthcare-related SAB (IE: 12%, aOR = 2.3, CI = 1.4-3.5). S.
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aureusmeningitis (IE: 59%), persistent bacteremia at 48 hours (IE: 25%) and C-reactive
protein > 190 mg/L (IE: 15%) were also independently associated with IE. Criteria for severe
sepsis or septic shock were met in 30% of SAB without IE (overall in hospital mortality rate
24%) and in 51% of IE (overall in hospital mortality rate 35%).
Conclusion
SAB is still a severe disease, mostly related to healthcare in a high-income country. IE is the
most frequent complication and occurs frequently in patients without known
predisposing conditions.
Introduction
Staphylococcus aureus is a common cause of bloodstream infection in high- income countries
[1,2], with an estimated incidence between 80 and 190 cases / 100.000 inhabitants per year.
This would represent an estimated 600.000 cases per year in the USA and 125.000 in France
[2]. S. aureus bloodstream infection (SAB) incidence may be increasing, at least in some re-
gions [3–5], probably due to higher numbers of invasive procedures and/or at-risk situations,
including the presence of endovascular devices. In recent series, SAB was associated with high
morbidity and a 20% or more case fatality rate [6]. However, large prospective epidemiological
studies of SAB have been rare since 2000 [7–12].
SAB represents two distinct clinical entities that differ in terms of management and progno-
sis [1]: SAB without any detected deep focus of infection for which a treatment duration of
14 days is recommended, and those associated with a deep infectious focus (whether cause or
consequence of bacteremia) which represent 40 to 70% of SAB cases and should be treated for
4 to 6 weeks. The most frequent reported deep infectious foci are endovascular foci including
infective endocarditis (IE), central nervous system, bone and joint, soft tissue and intra abdom-
inal/pelvic infections.
Among SAB with a deep focus of infection, those associated with IE are of particular interest
since they are the most frequent and have the poorest prognosis whether endovascular infec-
tion be the cause or the consequence of SAB. Furthermore, S. aureus has become, during the
last decade, the leading cause of IE in Western Europe and North America [13–15], and a mi-
croorganism clearly identified in IE patients, as responsible for the highest rates of morbidity
and mortality [14–16]. Frequency of IE in SAB patients varies according to studies from 10 to
46%, likely due to varying proportions of subjects with IE risk factors in these populations (e.g.
injecting drug use, prosthetic valve or underlying heart disease) [17]. Detection of IE in SAB
patients leads to adaptation of antibiotic therapy doses and duration. Early detection of IE may
also be beneficial by allowing early heart surgery when necessary [18]. The systematic use of
echocardiography in SAB remains however a matter of debate [1,19–21].
We conducted a large prospective exhaustive cohort study in 8 university hospitals in
France during a 30-month period, to (i) update the information on the epidemiology of SAB in
a high-income country, (ii) evaluate the frequency of different deep foci of infection including
IE and (iii) identify factors associated with IE in case of SAB.
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Materials and Methods
Ethics
The “Comité de Protection des Personnes Sud-Méditerranée IV” approved the study. The
VIRSTA study is registered in the European Clinical Trials Database (EUDRACT) under the
number: 2008-A00680-55. According to French legislation, and because no intervention was
performed on patients, no written informed consent was given by the patients. Patients records
and informations were anonymized and de-identified prior to analyses.
Study population—collected data
All consecutive adult patients hospitalized in the participating hospitals (see Appendix) with
SAB diagnosed between 1st April 2009 and 31st October 2011 were prospectively enrolled. SAB
was defined as at least one blood culture bottle collected in a participating hospital and yielding
S. aureus. Patients presenting with catheter colonization without SAB, defined as blood cul-
tures positive only in bottles collected through a vascular access line were excluded.
Patients were examined and treated according to usual hospital procedures. Echocardiogra-
phy was encouraged but was not mandatory for patient’s enrolment.
Trained research assistants prospectively collected clinical, biological and therapeutic data
through a standardized case report form in each center. Clinical data included demographics,
background characteristics (comorbidities, IE-predisposing conditions), healthcare contacts
within the 90 days preceding hospitalization including invasive procedures, and setting of ac-
quisition as defined below. SAB characteristics were recorded. These characteristics comprised
presumed source of infection as defined by the clinician in charge of the patient and deep foci
of infection (endocardium, lung and pleura, bones and joints, muscles, urine, central nervous
system) as attested by imaging studies or positive culture of a normally sterile site. Detailed re-
sults of echocardiography were recorded, including regurgitation, vegetation, abscess and pros-
thesis dehiscence. Bacteriological data included susceptibility to main antistaphylococcal
antibiotics and date and results of blood cultures. Therapeutic data included antibiotics, cathe-
ter removal, surgery, and admission to intensive care unit (ICU). All patients, their relatives or
physicians were contacted 12 weeks after the beginning of the SAB to check if patients were
alive, and survivors at week 12 were asked if they were able to engage in their usual activities
using a five-item questionnaire.
Setting of acquisition—definitions
Healthcare-associated SAB was defined as either nosocomial or non-nosocomial healthcare-
associated infection [13]. Nosocomial SAB was defined as infection developing in a patient hos-
pitalized for more than 48 hours prior to the onset of signs/symptoms consistent with blood-
stream infection. Non-nosocomial healthcare-associated infection was defined as SAB
diagnosed within 48 hours of admission in an outpatient with extensive healthcare contact as
reflected by any of the following criteria: (1) received intravenous therapy, wound care, or spe-
cialized nursing care at home within the 30 days prior to the onset of SAB; (2) attended a hospi-
tal or hemodialysis clinic within the 30 days before the onset of SAB; (3) was hospitalized in an
acute care hospital for 2 or more days in the 90 days before the onset of SAB; or (4) resided in a
nursing home or long-term care facility. Community-acquired SAB was defined as SAB diag-
nosed within 48 hours of admission in a patient who did not fit the criteria for healthcare-
associated infection.
Staphylococcus aureus Bloodstream Infection and Endocarditis
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Infective endocarditis classification
A local adjudication committee made up of cardiologists, infectious diseases specialists and
bacteriologists classified all SAB cases in each participating hospital as definite, possible or ex-
cluded IE according to the modified Duke criteria [22].
Statistical analyses
Factors associated with definite IE according to modified Duke criteria were analyzed using
multivariable logistic regression in the subpopulation of patients who were not referred to the
participating hospital for the management of IE. Because our purpose was to identify patients
with IE within the first 48 hours of care, we only included values that were present during the
first 48 hours of SAB diagnosis. Similarly, we defined persistent bacteremia as positivity of
blood cultures at 48 hours or later. Variables were selected to enter the model if they were asso-
ciated with outcome with a p-value< 0.10 in bivariate analysis. A stepwise backward proce-
dure was used to select the variables with a p-value< 0.05 in the final adjusted model.
We first performed the analysis in the whole population including predisposing heart condi-
tions and setting of SAB acquisition as explicative variables. Secondly, as setting of acquisition
and previously known IE predisposing conditions are known variables at the beginning of SAB
care, we calculated the proportion of IE according to both setting of acquisition and predispos-
ing conditions and then performed the analyses in sub-groups of patients: patients with or
without previously known IE predisposing conditions, patients with community or non-noso-
comial healthcare related, or nosocomial SAB.
Finally, in sensitivity analyses, we studied the factors associated with IE in the population of
patients who underwent echocardiography, where only those patients fulfilling a major echo-
cardiographic criterion in the modified Duke classification or having bacteriologically and/or
histologically proven IE were classified as definite IE. Analyses were performed with SAS soft-
ware (version 9.3).
The study is reported according to the STROBE statement for reporting observational stud-
ies [23].
Results
Study population
A total of 2091 patients with SAB were enrolled. After exclusion of the 83 patients referred to
the participating hospital for the management of IE, 2008 patients were kept for the analyses.
Main characteristics of patients are described in Table 1. Most patients had severe comorbidi-
ties including rapidly or ultimately fatal disease in 55.7%. Only 63 patients (3.1%) were past or
current injecting drug users. Previously known IE predisposing heart conditions were reported
in 24.4% of patients (prosthetic valve in 7% and native valve disease in 17.4%).
Presumed setting of acquisition was nosocomial in 1075 patients (53.5%), with an estimated
incidence of nosocomial SAB of 0.159/1000 patients-days of hospitalization in the participating
centers (95% confidence interval: 0.111–0.219). Frequency of methicillin-resistance was 19% in
the whole population, 9.8% in community-acquired SAB and 22.3% in healthcare-associated
SAB (21.7% in nosocomial, 24.4% in non-nosocomial).
Deep foci of infection
At least one echocardiography was performed in 1348 patients (67.1%), among whom 605
(30.1% of the whole population) had at least one transesophageal echocardiography. Echocar-
diography was performed significantly more frequently in patients with IE-predisposing
Staphylococcus aureus Bloodstream Infection and Endocarditis
PLOS ONE | DOI:10.1371/journal.pone.0127385 May 28, 2015 4 / 14
condition (data not shown). A deep focus of infection was detected in 36.6% of patients. Defi-
nite IE was the most frequent deep focus of infection, found in 221 out of 2008 patients
(11.0%), followed by bone and articulations and lungs localizations. When restricting the pop-
ulation to the subjects who underwent echocardiography, frequency of IE was 15.6% (n = 210).
Main characteristics of IE are described in Table 2 and main deep foci in patients with SAB
without IE in Table 3.
Table 1. Main characteristics of the 2008 patients with Staphyloccus aureus bloodstream infection en-
rolled in the VIRSTA study, 2009–2011.
Baseline characteristics
Median age (years) (IQR) 70 (58–81)
Male gender 1295 (64.5%)
Diabetes mellitus 857 (42.7%)
Hemodialysis 211 (10.5%)
Immunodepression 738 (36.8%)
McCabe score:
- ultimately fatal disease 751 (37.4%)
- rapidly fatal disease 368 (18.3%)
Injecting drug use 63 (3.1%)
Known heart disease predisposing to IE
- none 1518 (75.6%)
- prosthetic valve 140 (7.0%)
- native valve disease 350 (17.4%)
Cardiac device* 217 (10.8%)
Presumed source of SAB
- unidentiﬁed 406 (20.2%)
- skin 384 (19.1%)
- urinary tract 103 (5.1%)
- lung 122 (6.1%)
- peripheral venous line 143 (7.1%)
- central venous line 365 (18.2%)
- arterial line 19 (0,9%)
- arteriovenous ﬁstula 42 (2.1%)
- intravenous drug use 35 (1.7%)
- surgery 303 (15.1%)
- other 86 (4.3%)
Presumed place of acquisition
- unknown 58 (2.9%)
- community 522 (26.0%)
- non-nosocomial health care-related 353 (17.6%)
- nosocomial 1075 (53.5%)
Penicillin resistance 1808 (90.3%)
Methicillin resistance 381 (19.0%)
Complicated SAB 734 (36.6%)
Infective endocarditis 221 (11.0%)
Abbreviations: IQR: interquartile range; IE: infective endocarditis; SAB: Staphylococcus aureus
bloodstream infection.
* Pacemaker or implantable cardiovertor deﬁbrillator.
doi:10.1371/journal.pone.0127385.t001
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Table 3. Complication and outcome of the 1787 Staphylococcus aureus bloodstream infections with-
out infective endocarditis, VIRSTA Study 2009–2011.
Characteristics and outcome n (%)
Deep focus of infection 513 (28.7%)
- lung 141 (7.9%)
- urinary tract 94 (5.3%)
- vertebral osteomyelitis 48 (2.7%)
- prosthetic joint 66 (3.7%)
- other osteo-articular infections 110 (6.2%)
- myositis 38 (2.1%)
- central nervous system 16 (0.9%)
Severe sepsis without septic shock 208 (11.6%)
Septic shock 254 (14.2%)
In-hospital death 440 (24.6%)
12 week case-fatality rate 559 (31.3%)
doi:10.1371/journal.pone.0127385.t003
Table 2. Description of the 221 infective endocarditis diagnosed among the 2008 patients enrolled in
the VIRSTA study, 2009–2011.
Characteristics and outcome n (%)
Median age (years) (IQR)
Male gender 144 (65.2%)
Location of IE
- aortic 39 (17.7%)
- mitral 61 (27.0%)
- aortic and mitral 21 (9.5%)
- right-sided 17 (7.7%)
- bilateral 20 (9.1%)
- cardiac device only* 7 (1.8%)
- undetermined 56 (25.3%)
Classiﬁcation according to modiﬁed Duke criteria
- surgically deﬁnite 24 (10.9%)
- clinically deﬁnite 197 (89.1%)
- 2 major criteria 139 (62.9%)
- 1 major criterion,  3 minor criteria 56 (25.3%)
- 5 minor criteria 2 (0.1%)
Severe sepsis without septic shock 56 (25.3%)
Septic shock 57 (25.8%)
Stroke 47 (21.2%)
Other embolic event 67 (30.3%)
Staphylococcus aureus meningitis 13 (5.9%)
Brain abscess 8 (3.6%)
Vertebral osteomyelitis 20 (9.0%)
In-hospital death 78 (35.3%)
12 week case-fatality rate 87 (39.4%)
Abbreviations: IQR: interquartile range; IE: infective endocarditis.
doi:10.1371/journal.pone.0127385.t002
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Follow-up
Main complications and outcomes are described in Table 2 for patients with IE and in Table 3
for patients without IE. Complications occurred more frequently in patients with IE. In-hospi-
tal global mortality was 25.8%, 24.6% in patients without IE vs 35.3% in patients with IE
(p = 0.003). Mortality at 12 weeks was 32.2%, 31.3% in patients without IE vs 39.4% in patients
with IE (p = 0.03). In survivors, inability to engage in usual activities 12 weeks after occurrence
of SAB was common (56%), with no significant difference between patients with and without
IE.
Adjusted analyses of factors associated with IE
Table 4 presents the crude frequencies of IE according to main characteristics of patients, as
well as crude and adjusted odds-ratios (aOR) in the models performed on the whole population
of 2008 patients. Table 5 presents the crude proportion of IE according to both setting of acqui-
sition and predisposing heart condition.
The following factors were not associated with IE in univariate analyses with a p> 0.10:
age, sex, dialysis, McCabe score, penicillin sensitivity.
The risk of IE was strongly associated with predisposing condition, i.e. heart disease and in-
jecting drug use. However, the frequency of IE in patients without underlying heart condition
was 7.0% globally and 3.9% among patients with nosocomial SAB. Globally, the proportion of
patients with IE and without predisposing condition, was 39.8% (Table 5). We also observed
that IE was more frequent in patients who acquired SAB outside the hospital as compared to
nosocomial SAB, with aORs of 2.9 for community SAB and 2.2 for non-nosocomial health-
care-associated SAB in the whole-population analysis. These associations were observed in pa-
tients with and without underlying heart condition (data not shown).
Severe sepsis during the first 48 hours was independently associated with IE, as well as high
levels of C-reactive protein. Duration of bacteremia> 48 hours was strongly associated with
the presence of IE. Early embolic events and meningitis were also associated with IE.
The percentage of variability explained by the multivariable model was low, as attested to by
the pseudo-R2 of 0.37 for the final model in the whole population. The sensitivity analyses per-
formed in the subpopulation of the 1348 patients who underwent echocardiography and con-
sidering only definite IE defined surgically or echocardiographically, yielded similar results
(data not shown).
Discussion
In this large prospective study, SAB was associated with high morbidity and mortality. A deep
focus of infection was identified in more than one third of patients, including IE in 11%, which
was the most frequent complication and was associated with a poorer outcome. Frequency of
IE varied according to predisposing heart condition, setting of acquisition with a decreasing
gradient of frequency between community, outpatient healthcare and hospital, and to some pa-
rameters available at the early stage of management including C-reactive protein and duration
of bacteremia. A high proportion of IE occurred in patients who had no known
predisposing condition.
Our study is the largest prospective cohort of SAB reported to date [9,24–25]. We compre-
hensively enrolled consecutive patients, which reduced the risk of selection bias. The study was
performed in eight different hospitals located in different regions in France; results should thus
be more generalizable than those yielded in a monocentric study. Thus, we believe that this
study provides accurate estimates of the risk of IE in case of SAB in various settings and among
patients with various predisposing conditions in high-income countries.
Staphylococcus aureus Bloodstream Infection and Endocarditis
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Table 4. Factors associated with Infective Endocarditis in the whole population, VIRSTA study 2009–2011.
Factor studied All patients with
SAB (n = 2008)
Patients with IE
(n = 221) N (%)
Crude
OR
95%
CI
Crude p-
value
Adjusted
OR
95%
CI
Adjusted p-
value
Baseline characteristics
Diabetes mellitus 0.002
No 1441 196 (14) 1
Yes 567 25 (4) 0.60 0.4–
0.8
Intravenous drug use < 0.0001 < 0.0001
No 1945 197 (10) 1 1
Yes 63 24 (38) 5.46 3.2–
9.3
5.41 2.7–
10.9
Immunodepression 0.06
No 1270 152 (12) 1
Yes 738 69 (9) 0.76 0.6–
1.0
Known heart disease predisposing to
IE
< 0.0001 < 0.0001
- none 1518 106 (7) 1 1
- prosthetic valve 140 46 (33) 6.52 4.4–
9.8
9.66 5.8–
16.0
- native valve disease 350 69 (20) 3.27 2.4–
4.6
4.06 2.8–
6.0
Intracardiac device 0.0006
No 1791 181 (10) 1
Yes 217 40 (18) 2.01 1.4–
2.9
Initial SAB characteristics
Presumed source < 0.0001
Unidentiﬁed 406 60 (15) 1.38 0.9–
2.1
Skin 384 43 (11) 1
Intravenous drug use 35 18 (51) 8.40 4.0–
17.5
Urinary tract 103 13 (13) 1.15 0.6–
2.2
Lung 122 3 (3) 0.20 0.1–
0.7
Surgery 303 29 (10) 0.84 0.5–
1.4
Venous peripheral line 143 9 (6) 0.53 0.2–
1.1
Venous central line 365 24 (7) 0.56 0.3–
0.9
Arterial line 19 2 (10) 0.93 0.2–
4.2
Arteriovenous ﬁstula 42 9 (21) 2.16 1.0–
4.8
Other 86 11 (13) 1.16 0.6–
2.4
Presumed place of acquisition < 0.0001 < 0.0001
Community 522 107 (21) 3.76 2.7–
5.2
2.88 1.9–
4.3
(Continued)
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Table 4. (Continued)
Factor studied All patients with
SAB (n = 2008)
Patients with IE
(n = 221) N (%)
Crude
OR
95%
CI
Crude p-
value
Adjusted
OR
95%
CI
Adjusted p-
value
Non-nosocomial health care 353 42 (12) 1.97 1.3–
3.0
2.22 1.4–
3.5
Hospital 1075 69 (6) 1 1
Unknown 58 3 (5) 0.80 0.2–
2.6
0.69 0.2–
2.7
Duration of symptoms before
collection of blood culture
< 0.0001
< 1 day 945 74 (8) 1
> 1 day 983 142 (14) 1.99 1.5–
2.7
Unknown 80 5 (6) 0.78
Penicillin resistance 0.35
Yes 1808 195 (11) 1
No 200 26 (13) 1.24 0.8–
1.9
Methicillin resistance 0.02
Yes 381 30 (8) 1
No 1623 191 (12) 1.56 1.0–
2.3
C-reactive protein > 190 mg/L < 0.0001 0.0003
No 952 72 (8) 1 1
Yes 929 141 (15) 2.19 1.6–
3.1
1.91 1.3–
2.7
Missing value 127 8 (6) 0.78 0.3–
1.7
0.76 0.3–
1.7
Early events (available within the
ﬁrst 48 hours of diagnosis)
Severe sepsis or septic shock < 0.0001 0.0005
No 1513 126 (8) 1 1
Yes 495 95 (19) 2.61 2.0–
3.5
1.89 1.3–
2.7
Stroke < 0.0001 < 0.0001
No 1962 193 (10) 1 1
Yes 46 28 (61) 14.3 7.7–
26.2
7.50 3.3–
16.8
Other embolic event < 0.0001 < 0.0001
No 1955 188 (10) 1 1
Yes 53 33 (62) 15.5 8.7–
27.6
10.5 5.0–
21.8
Meningitis < 0.0001 < 0.0001
No 1986 208 (11) 1 1
Yes 22 13 (59) 12.3 5.2–
29.2
8.32 2.7–
25.4
Vertebral osteomyelitis 0.01
No 1980 213 (11) 1
Yes 28 8 (29) 3.32 1.4–
7.6
Persistent bacteremia at 48 hours < 0.0001 < 0.0001
No 1664 136 (8) 1 1
(Continued)
Staphylococcus aureus Bloodstream Infection and Endocarditis
PLOS ONE | DOI:10.1371/journal.pone.0127385 May 28, 2015 9 / 14
The incidence of nosocomial SAB was high in the 8 participating centers, albeit similar to
that observed in other high-income countries [26,27]. Healthcare-related SAB were the most
frequent, representing 70% of cases in our study, a proportion similar to that reported in other
contemporary studies [3,4,9]. Thus, it seems essential to improve the prevention of this dread-
ful complication of medical progress. In Australia, implementation of non-specific infection
prevention and control initiatives was associated with a substantial reduction of the incidence
of nosocomial SAB [28]. Recent studies have suggested that universal decontamination may
also be useful, especially in the ICU [29,30]. Approximately one in five SAB in our study were
healthcare-associated but non-nosocomial. The use of outpatient invasive medical therapy is
increasing and infection control is difficult to implement in this setting. The impact of preven-
tive measures, such as S. aureus nasal decontamination in patients receiving outpatient intrave-
nous therapy should be a matter of clinical research.
We observed IE of 11% of our population. As echocardiography was performed in only 60%
of study patients, this estimation is probably conservative. In studies with more systematic use
of echocardiography, the proportion of IE was higher, around 20% [9,20,31]. However, under-
estimation of IE was probably not major in our study, as the proportion of IE was not much
higher (i.e. 15.6%) in the subgroup of patients who underwent echocardiography. The differ-
ence in rates of IE reported in the literature may be due to differences in proportion of at-risk
populations enrolled in the studies. In fact, the frequency of IE varies widely across strata of
risk factors. For example, in our study, IE frequency varied from 38% in injecting drug users
and 33% in patients with prosthetic heart valve, to 4% in patients with nosocomial SAB in the
absence of underlying heart condition, the strata of patients with the lowest rate of IE.
We observed a quite low rate of deep foci of infection other than IE in this cohort, compared
to other cohort studies of SAB [10]. This may be the consequence of the high proportion of
nosocomial SAB in our study. Nosocomial SAB originate mostly from venous access and are
usually diagnosed and managed early, which may lead to a lower risk of metastatic spread of in-
fection compared to SAB occurring outside the hospital who may be referred later in
Table 4. (Continued)
Factor studied All patients with
SAB (n = 2008)
Patients with IE
(n = 221) N (%)
Crude
OR
95%
CI
Crude p-
value
Adjusted
OR
95%
CI
Adjusted p-
value
Yes 344 85 (25) 3.69 2.7–
5.0
4.01 2.8–
5.7
Abbreviations: SAB: Staphylococcus aureus bacteremia; IE: infective endocarditis; OR: Odds-ratio; CI: conﬁdence interval.
doi:10.1371/journal.pone.0127385.t004
Table 5. Rate of IE according to predisposing heart disease and setting of acquisition.
Setting of acquisition Predisposing heart disease Total
Yes, prosthetic Yes, native No
Community associated—intravenous drug use 2/2 (100%) 1/3 (33.3%) 18/38 (47.4%) 21/43 (48.8%)
Community associated—non intravenous drug use 20/30 (66.7%) 31/80 (38.8%) 35/369 (9.5%) 86/479 (18.0%)
Non-nosocomial healthcare associated 6/13 (46.2%) 15/66 (22.7%) 21/274 (7.7%) 42/353 11.9%
Nosocomial 18/94 (19.1%) 20/191 (10.5%) 31/790 (3.9%) 69/1075 (6.4%)
Unknown 0/1 (0%) 2/10 (20%) 1/47 (2.1%) 3/58 (5.2%)
Total 46/140 (32.9%) 69/350 (19.7%) 106/1518 (7%) 221/2008 (11%)
doi:10.1371/journal.pone.0127385.t005
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presentation. This is also a plausible explanation for the lower risk of IE in patients with noso-
comial SAB.
Among factors associated with IE we observed, most are longtime known, they are predis-
posing conditions to IE like heart valve disease or injecting drug use or direct complication of
IE like stroke. Some factors have been identified more recently in smaller studies [17,25,32,33].
Among the latter, the most striking is persistent bacteremia, which was associated with a higher
frequency of IE whatever the setting of acquisition and the presence of IE predisposing condi-
tion. Such an association between duration of bacteremia and IE may be either a cause or a
consequence of IE. Nevertheless, this finding emphasizes the necessity of systematically draw
follow-up blood cultures during the first days of management of SAB.
A finding which has not been previously reported to our knowledge is the higher frequency
of IE in non nosocomial healthcare-related SAB compared to those acquired in the hospital.
The decreasing gradient of frequency of IE complicating SAB between community, outpatient
healthcare and hospital may be explained by (i) a higher proportion of identifiable and remov-
able primary focus, mostly venous access, in outpatient healthcare-related infections compared
to community-acquired ones and (ii) a later diagnosis of infection in outpatients compared to
inpatients. Earlier management of bacteremia may also be an explanation for the lower rate of
IE observed in unadjusted analyses in patients with diabetes mellitus or immunodepression.
We also found higher C-reactive protein in the first 48 hours as associated with IE. This biolog-
ical marker may thus be useful in the early management of SAB, indicating when elevated a
higher risk for complicated infection, possibly through a higher bacterial load. Lastly, meningi-
tis is rare during SAB but very frequently associated with IE and appears thus to be a useful
clue in clinical care.
Nevertheless, our multivariable model did explain only a low proportion of the variability,
which suggests that many factors favoring a location in the endocardium in case of SAB still re-
main to be discovered. This point is also illustrated by the fact that 40% of IE occurred in pa-
tients without predisposing condition and by the relatively high proportion of IE in patients
without underlying heart disease (7%), even in case of nosocomial acquisition of bacteremia
(4%). The impact of bacterial genotype or virulence factors has still to be better understood
[34–36]. Impact of host genetic background has never been studied to our knowledge. More-
over, because most factors associated with IE are not strongly discriminant, it seems rather dif-
ficult to rule out IE in a patient with SAB without actively searching for IE by performing
transthoracic or transesophageal echocardiography. An ecological study performed in the
Netherlands recently suggested that routine use of echocardiography in case of Gram-positive
bacteremia is associated with a higher rate of IE diagnosis and a lower risk of death in case of
IE, which suggests that early detection of IE is beneficial [20]. Indeed, the 2009 European
guidelines on IE diagnosis, prevention and treatment recommend performing echocardiogra-
phy in all patients with SAB [37]. By providing estimates of frequency of IE in case of SAB, our
data may help the clinician on the decision to perform this exploration.
This study has some limitations. First, patients were enrolled in tertiary care centers. This
has probably led to the recruitment of more severe patients with a higher prevalence of comor-
bidities leading to a possible overestimation of frequency of poor outcomes. However, we mini-
mized the referral bias by excluding from analyses of risk factors for IE those patients referred
for management of IE. Second, as the study was observational, we could not control for
any factor.
Our findings underscore the need to promptly detect and manage deep foci of infection
when SAB is diagnosed. Among those foci, IE is the most frequent. The frequency of IE varies
widely according to setting of acquisition and medical conditions but is not associated with any
known predisposing condition in 40% of patients. It seems thus important to look for the
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association between S. aureus IE and yet unknown factors like host and bacterium genetic
background. The prevention of SAB is an urgent goal for infection control in hospital and
outpatient healthcare.
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